Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus ATENOLOL AND CHLORTHALIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus ATENOLOL AND CHLORTHALIDONE.
ANHYDRON vs ATENOLOL AND CHLORTHALIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
1 tablet (atenolol 50 mg/chlorthalidone 25 mg) orally once daily. May be increased to 2 tablets once daily.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Atenolol: 6-7 hours (prolonged to 14-27 hours in severe renal impairment); Chlorthalidone: 40-60 hours (allows once-daily dosing).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Atenolol: ~50% eliminated unchanged in urine; Chlorthalidone: ~50-70% eliminated unchanged in urine, remainder as metabolites via renal and biliary routes (<10% fecal).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic